Our data is supported by previous studies showing that glucagon antagonism mitigates diabetic cardiomyopathy in Leprdb/db diabetic mice, coinciding with improved whole body insulin signalling [53]. This evidence concerns the gene INS and diabetic cardiomyopathy.